SIG-003

SIG-003 is a preclinical-stage therapeutic candidate developed by Sigilon Therapeutics (now a subsidiary of Eli Lilly) for the treatment of Hemophilia B, a rare genetic bleeding disorder characterized by a deficiency in coagulation factor IX. The drug utilizes Sigilon's proprietary Shielded Living Therapeutics (SLTx) platform, which involves the encapsulation of engineered human cells within a biocompatible hydrogel matrix (Afibromer). These engineered cells are designed to continuously produce and secrete functional factor IX into the patient's systemic circulation. The encapsulation technology is intended to protect the therapeutic cells from the host's immune system and prevent the formation of fibrotic capsules, potentially allowing for long-term protein replacement without the need for chronic immunosuppression. SIG-003 is typically administered via laparoscopic implantation into the peritoneal cavity.